Search
for
Sort by
Research 31–60 of 682
- Neuroactive Steroids and Ethanol Exposure: Relevance to Ethanol Sensitivity and Alcohol Use Disorders Risk
- Risk of Psychiatric Disorders following Polycystic Ovary Syndrome: A Nationwide Population-Based Cohort Study
- STEROIDS AND STEROID-LIKE COMPOUNDS
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Sex dependent influence of a functional polymorphism in steroid 5‐α‐reductase type 2 (<i>SRD5A2</i>) on post‐traumatic stress symptoms
- Effect of Exercise Interventions on Metabolic, Reproductive and Mental Health in Overweight Women with Polycystic Ovary Syndrome
- Post-acute COVID-19 symptom risk in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis
- Is polycystic ovary syndrome a risk factor for depression and anxiety?: a cross-sectional study
- Finasteride prescribed for hair loss consistently leads to depression. Comment on ‘Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement’
- The Effect of Sex on the Risk of Long-COVID and Cardiovascular Complications in Healthy Patients without Comorbidities: Data from a Polish Long-COVID Cardiovascular (PoLoCOV-CVD) Study
- Finasteride Use: Evaluation of Depression and Suicide Risk
- Public Awareness of the Symptoms and Risk Factors of Thyroid Disease in Saudi Arabia
- Persistent scurvy after vitamin C supplementation in a high-risk patient: a case report
- The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations
- Finasteride, pharmacogenomics, and suicide risk: a public health concern
- The Genetic Landscape of Androgenetic Alopecia: Current Knowledge and Future Perspectives
- Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
- Synthesis and Actions of 5α-Reduced Metabolites of Testosterone in the Nervous System
- Assessing the Environmental and Health Adverse Effects of Mercury Released From Dental Amalgam: A Literature Review
- Long COVID syndrome: An unfolding enigma
- Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence
- EFFECTS OF HORMONAL THERAPY IN TRANSGENDERS
- Dermatological Manifestations of Stress in Normal and Psychiatric Populations
- Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies
- Frontotemporal dementia with parkinsonism presenting as posterior cortical atrophy
- Ischemic Stroke in a Young Adult Male During Finasteride Therapy
- Comparison of Complications after Coronavirus Disease and Seasonal Influenza, South Korea